Escherichia coli vaccine - MedImmune

Drug Profile

Escherichia coli vaccine - MedImmune

Alternative Names: MEDI 516; Urinary tract infections vaccine - Medimmune; UTI vaccine - MedImmune

Latest Information Update: 21 Jun 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Washington University
  • Developer Chiron Corporation; Washington University
  • Class Escherichia coli vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Urinary tract infections

Most Recent Events

  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
  • 31 Dec 2002 Discontinued - Phase-II for Urinary tract infections in USA (IM)
  • 21 Mar 2001 MedImmune has initiated a second phase II trial of its UTI vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top